Molnupiravir: A New Treatment for COVID-19
Overview of Molnupiravir
Molnupiravir, a broad-spectrum antiviral, has received approval in the U.K. for the treatment of COVID-19. Extensive research has been conducted since the pandemic began, focusing on new treatments and prevention strategies for the virus. Various existing medications, including hydroxychloroquine, ivermectin, and remdesivir, have been repurposed to explore their antiviral or immune-supportive properties. The availability of pharmaceutical treatments is crucial, especially for individuals who cannot or choose not to get vaccinated.
Herd immunity, which occurs when a significant portion of a population becomes immune to a disease, has not yet been achieved globally. This immunity is essential for protecting unvaccinated individuals and reducing the overall burden of COVID-19.
Molnupiravir was developed about a decade ago and initially tested in Liberia in 2016 for its potential to prevent complications from the Ebola virus. It is currently undergoing clinical trials to assess its effectiveness in treating symptomatic COVID-19 cases caused by the SARS-CoV-2 virus. Early results are promising; a clinical trial conducted by Merck and Ridgeback indicated that COVID-19 patients treated with molnupiravir were approximately 50% less likely to be hospitalized or die within 30 days of treatment. Additionally, this study showed that patients receiving molnupiravir developed antibodies against SARS-CoV-2 at rates similar to those who received a placebo, suggesting that the drug does not hinder the immune system’s ability to respond to the virus. Furthermore, molnupiravir is being evaluated for use in post-exposure prophylaxis, aimed at preventing COVID-19 after exposure to the virus.
Mechanism of Action
As an antiviral agent, molnupiravir is designed to alleviate the symptoms associated with viral infections, particularly those caused by RNA viruses like SARS-CoV-2. It functions as a prodrug, converting into a chemical compound known as beta-D-N4-hydroxycytidine (BHC) upon metabolism in the body. This conversion prompts the virus to undergo mutations that can prove detrimental to its survival, thereby impacting its ability to replicate and reducing viral load. Research indicates a potential link between high levels of the SARS-CoV-2 virus in nasal passages and increased hospitalization rates.
Potential Side Effects
Current studies indicate that molnupiravir is generally well tolerated at standard doses, exhibiting a relatively mild side effect profile. Commonly reported side effects include headache, insomnia, dizziness, and diarrhea. In the clinical trial by Merck and Ridgeback, four patients experienced serious side effects, which included two hospitalizations due to reduced oxygen saturation, one case of acute respiratory failure, and one cerebrovascular accident, characterized by significant blood flow loss to the brain. However, it remains unclear whether these serious side effects were due to the drug or the underlying complications associated with COVID-19.
While evidence suggests that molnupiravir may effectively reduce the progression of symptomatic COVID-19, further research is required to confirm its efficacy and safety.
References
1. Johns Hopkins Bloomberg School of Public Health (2021, October 18). Molnupiravir: The Game-Changing Antiviral Pill for COVID-19? Johns Hopkins University: Baltimore, MD. Accessed 2021, November 15, from https://publichealth.jhu.edu/2021/molnupiravir-the-game-changing-antiviral-pill-for-covid-19
2. Centers for Disease Control and Prevention (2021, March 23). Potential Treatments. U.S. Department of Health and Human Services. Accessed 2021, November 22, from https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html
3. Aschwanden, C. (2021, March 18). Five reasons why COVID herd immunity is probably impossible. Nature Portfolio. Accessed 2021, November 22, from https://www.nature.com/articles/d41586-021-00728-2
4. Association for Professionals in Infection Control and Epidemiology (APIC) (2021, April 6). Herd Immunity. Arlington, VA, USA. Accessed 2021, November 22, from https://apic.org/monthly_alerts/herd-immunity/
5. Merck (2021, October 1). Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Merck Sharp & Dohme Corp., Merck & Co. Accessed 2021, November 22, from https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderate/
6. Fischer, W., Joseph, J., Holman, W., et al (2021, June 17). Molnupiravir, an Oral Antiviral Treatment for COVID-19. MedRxiv. Doi: 10.1101/2021.06.17.21258639
7. Precision Vaccinations (2021, September 1). Phase 3 Study Evaluating Oral Antiviral for Post-Exposure Prophylaxis of COVID-19. Precision Vax LLC. Accessed 2021, November 22, from https://www.precisionvaccinations.com/2021/09/01/phase-3-study-evaluating-oral-antiviral-post-exposure-prophylaxis-covid-19-infection
8. Painter, W.P., Holman, W., Bush, J.A., et al (2021, April 19). Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2. Antimicrobial Agents and Chemotherapy 65(5): 10.1128/AAC.02428-20
9. Chen, J., Qi, T., Liu, L., et al (2020, May). Clinical progression of patients with COVID-19 in Shanghai, China. Journal of Infection 80(5): e1-e6. Doi: 10.1016/j.jinf.2020.03.004
10. National Cancer Institute (n.d.) NCI Dictionaries. National Institutes of Health: U.S. Department of Health and Human Services. Accessed 2021, November 23, from https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cerebrovascular-accident